Pharmaceutical Patent Protection in Turkey

June 2011

Abstract

Between 1994 and 1995, Turkey conducted necessary legislative studies to establish an efficient and contemporary industrial property system and obtained very important concrete results. Turkey has ratified many international agreements regarding the IP system and as a result of this, pharmaceutical products and their process procedures have also started to be protected by Intellectual Property (IP) rights since 1st January 1999. This means an important Turkish Industrial Property Revolution. The international agreements regarding the IP system are, PCT (Patent Cooperation Treaty) which has come into force in 1st January 1996 and the EPC (European Patent Convention) in 1st November 2000. As a result of these changes, Turkey has some problems as other developing countries during the transition periods concerning their IP system.

Author

Gaye Ramazanoglu Partlak

Intellectual Property Specialist, Sanovel Ilac San.ve Tic. A.S., Turkey

Biography Graduated from Marmara University, Faculty of Pharmacy in 2000. Started working for Roche Pharmaceuticals-Istanbul in September 2000 as Quality Control Analyst and later on worked as Analytical Method Validation Responsible and as Quality Assurance Specialist until February 2006. Then started working for Sanovel Pharmaceuticals-Istanbul as Intellectual Property Specialist at March 2006 and since then working still there. In 2007, took the Turkish national patent and trademark exams and passed in first trial to be a Patent and Trademark Attorney. Have a certificate from CEIPI (Centre for International Intellectual Property Studies) which is based in Strasbourg Law Faculty, about `Basic Training for the European Patent Law` (this course was held between 2008-2010 at Istanbul) Have a certificate from EPO (European Patent Office) as a `Praktika Intern`. I had training at DG1 - Pure and Applied Organic Chemistry Cluster in EPO, Munich (Germany) for 3 weeks in November, 2009.

Company

Sanovel Ilac San.ve Tic. A.S.

Sanovel Ilac (Pharmaceuticals), the fastest growing company in Turkish pharmaceutical market, has been established in 1983 by Pharmacist Erol Toksoz and has grown to be the flagship company in core business of Toksoz Group that manufactures, markets and distributes pharmaceutical products. Moving up in IMS ranking to be among top ten companies over the last decade, Sanovel has proven success record of developing and introducing value added and patented generic products to market in all vital therapeutic areas. Furthermore, Sanovel serves in animal health with its veterinary products. While growing in Turkey, Sanovel is also moving towards international recognition. Branch offices are already established in CIS, Ukraine and Russian Federation. Export to Georgia and Azerbaijan has started in 2005. At the same time the project for presence in EU and USA is also moving forward with companies established in Netherland (Adilna Sanovel Holding B.V.), France (Sanovel S.A.S), Germany (Sanovel GmbH) and Bulgaria (Sanovel L.L.C). The new Sanovel Production Site became operational in April-2006, in Silivri, with 40.000 m² closed area which is built upon 125,000 m² of land and approved from the EU authorities as EU GMP Production Site. Production Site consists of Main Production Unit, Cephalosporin Production Unit and Biotech Production Unit. The main production unit itself consists of solid production, semi-solid production, liquid production, primary and secondary packaging, shipping and receiving area. Production is completely performed in a closed system and all pharmaceutical forms can be manufactured. Company Philosophy The philosophy of Sanovel is to contribute to the whole of healthcare system to answer needs of consumers as well as needs of medical professionals. Mission Statement Our mission is to be a company of high quality standards, committed to medical ethics and customer satisfaction with environmental and social consciousness while embracing innovation, change and development. `Focus on Growth` has been the motto of Sanovel.

Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more

David Dolberg

Senior Director of Intellectual Property, Sanaria Inc., USA

Ways to Avoid Having your Patents Cellected*

The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more

Tom Irving

Partner, Marbury Law Group, USA

Xiaoguang Michelle Gao

Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA

Michelle E. O'Brien

Partner, Marbury Law Group, USA

Section 112 Requirements for Life Sciences Patents

35 U.S.C. §112(a) of the US Patent Act is one of the integral parts of the quid pro quo patent system that balances the benefit of disclosure of the invention...Read more

Anagha Tendulkar

In-house Patent Counsel, Cipla, India

A Current Look at the State of Inequitable Conduct and Other Equitable Concerns

Inequitable conduct is an “equitable defense to patent infringement that, if proved, bars enforcement of a patent. ” Therasense, Inc. v. Becton, Dickinson & Co. , 649 F. 3d 1276,...Read more

Tom Irving

Partner, Marbury Law Group, USA

Xiaoguang Michelle Gao

Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA

Stacy Lewis

Law Clerk, Finnegan, USA

Jordan Cowger

Finnegan, USA

Melissa Santos

Finnegan, USA

Pharmaceutical Patent Protection in Turkey

Abstract

Author

Company

Sanovel Ilac San.ve Tic. A.S.

Related Papers